Nuvo Research announced the FDA has approved Mallinckrodt’s Pennsaid (diclofenac sodium) topical solution 2% w/w.
Pennsaid 2% is a topical nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of osteoarthritis pain of the knee.
RELATED: Musculoskeletal Disorders Resource Center
Diclofenac inhibits the enzyme, cyclooxygenase (COX), an early component of the arachidonic acid cascade, resulting in the reduced formation of prostaglandins, thromboxanes and prostacylin.
Pennsaid 2% is a follow-on to the original Pennsaid 1.5% w/w that has been available since 2010. The new 2% topical solution is more viscous than original Pennsaid 1.5%.
Pennsaid 2% topical solution is supplied in a metered dose pump bottle. Mallinckrodt plans to launch Pennsaid 2% in the first quarter of 2014.
For more information, call (888) 744-1414 or visit Pennsaid.com.